IXICO raising up to £10.5m to develop AI neuroscience platform and pursue FDA approval

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics company, is raising up to £10.5 million through a combination of placings, a director subscription and a retail offer, as it seeks to accelerate development of its artificial intelligence-driven IXI platform and pursue US regulatory approval. The investment round comprises an initial placing of £2.8 million and a £0.1 million subscription by certain directors, both priced at 8p per share, representing a 1.6% premium to the closing price of 7.875p on Monday (30 March).